Quick Facts
| Property | Value |
|---|---|
| Category | Growth Hormone Secretagogue Stack |
| Risk Level | Moderate/High |
| Administration | Subcutaneous Injection |
| Typical Frequency | Nightly |
| Estimated Half-Life | Variable Depending on DAC vs No DAC Formulation |
| Primary Research Interest | HGH Support / Recovery / Fat Loss / Sleep Support |
This material is provided strictly for educational and informational purposes related to peptide research and endocrine compounds. CJC-1295 / Ipamorelin is a biologically active peptide stack capable of significantly altering growth hormone and IGF-1 signaling pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Reconstitution Guide
- Blend Composition: CJC-1295 5 mg / Ipamorelin 5 mg
- Blend Ratio: 1 : 1
- Total Vial Size: 10 mg total blend
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 2 mL
- Final Concentration: 5.00 mg/mL total blend concentration
At this concentration:
• 500 mcg = 0.100 mL (10.0 units)
2. Route of Administration
CJC-1295 / Ipamorelin is most commonly administered as a subcutaneous injectable growth hormone secretagogue stack.
- Primary Route: SubQ Injection
- Preferred Timing: Before bedtime
- Administration Notes: Bedtime administration is commonly used to align with natural nocturnal HGH pulses
3. Typical Research Protocols
- Product Strength: 5.00 mg/mL total blend concentration
- Typical Delivered Amount: 500 mcg every PM before bedtime
- Frequency: Every night at bedtime
- Cycle Length: 16 weeks on / 16 weeks off
- Special Notes: Whether the CJC-1295 component contains DAC or NO DAC dramatically changes the pharmacokinetics of the stack. NO DAC versions are commonly administered daily, while DAC-containing versions are often administered only once or twice weekly due to the substantially extended half-life.
4. Summary
CJC-1295 / Ipamorelin is a synergistic peptide stack designed to stimulate endogenous growth hormone release through complementary signaling pathways.
The combination is popular within body composition and recovery-focused peptide discussions because it attempts to enhance HGH signaling while minimizing some side effects associated with direct HGH administration.
5. Mechanism of Action
The stack combines two distinct growth hormone secretagogues:
- CJC-1295: A GHRH analog that stimulates pituitary HGH release
- Ipamorelin: A ghrelin receptor agonist that promotes HGH pulse signaling
- Increased endogenous HGH release
- Elevated IGF-1 signaling
- Improved recovery signaling
- Enhanced lipolysis support
- Improved sleep and recovery quality
6. Potential Benefits
- Potential fat loss support
- Enhanced recovery from training stress
- Improved sleep quality
- Increased endogenous HGH signaling
- Potential connective tissue support
- Possible lean body composition improvements
7. Potential Risks / Side Effects
Moderate/High
- Water retention
- Numbness or tingling
- Elevated hunger
- Insulin resistance concerns
- Headaches
- Potential endocrine dysregulation
- Elevated IGF-1 concerns
8. Half-Life
Half-life characteristics vary dramatically depending on whether the CJC-1295 component contains DAC.
NO DAC versions demonstrate substantially shorter activity windows, while DAC-containing versions may remain active for several days.
9. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
10. Contraindications / Warnings
- Active cancer or cancer history
- Pregnancy or breastfeeding
- Diabetes or insulin resistance
- Severe endocrine disorders
- Known hypersensitivity to peptide compounds
11. Research References
- PubMed
- NIH Publications
- Growth hormone physiology literature
- Peer-reviewed endocrinology journals
CKF Tide Tables 